Strata Critical Medical (SRTA) Q2 2026 earnings review
Accelerating M&A Masks Organic Logistics Cracks
Strata delivered a massive top-line beat in Q2, driving a full-year guidance raise. However, the composition of this growth reveals a bifurcated business. The newly formed Clinical segment is booming, fueled by three bolt-on acquisitions and gross margin expansion to 26.1%. Conversely, the legacy Logistics segment is decelerating (growth slowed to 6.9% YoY from 32.4% in Q1) and suffering margin compression down to 18.4%. Furthermore, GAAP net loss widened significantly to $(10.5) million, overshadowed by management's focus on a record $7.9 million Adjusted EBITDA.
🐂 Bull Case
The company executed three clinical bolt-on acquisitions in Q2, adding ~$6M in annualized Adjusted EBITDA at attractive mid-single-digit multiples. The clinical segment provides higher margins and lower capital intensity.
Strata generated $5.7M in operating cash flow and $2.9M in free cash flow, marking its second consecutive quarter of positive cash generation and proving the standalone medical model's viability.
🐻 Bear Case
Logistics gross margin compressed to 18.4% (down 160 bps YoY), and the segment faces a ~3% revenue headwind in Q3 due to a specific non-exclusive customer significantly reducing flying volume.
Net loss from continuing operations ballooned 208% YoY to $(10.5)M, severely disconnected from the $7.9M Adjusted EBITDA figure, driven by non-cash revaluations and heavy brand integration amortization.
⚖️ Verdict: ⚪
Neutral. The strategic pivot to Clinical is working brilliantly, but the core Logistics engine is showing organic fatigue. Investors are being asked to buy into a roll-up story while forgiving widening GAAP losses and declining legacy margins.
Key Themes
Aggressive Clinical Consolidation
Strata is aggressively executing its M&A playbook, closing three deals in Q2 alone (Ohio Valley Perfusion, Louisville Perfusion, and HLT-NRP). This strategy is deliberately shifting the business mix: Clinical is expected to represent nearly 50% of gross profit in H2 2026. The Clinical segment's gross margin expanded 110 bps sequentially to 26.1%, fundamentally altering the company's margin and capital intensity profile.
Logistics Margin Deterioration
Logistics gross margins fell to 18.4% in Q2, missing management's ~20% target. This was driven by a mix shift toward shorter, lower-margin trips, elevated unscheduled maintenance on the owned fleet, and the mechanical dilutive effect of higher fuel surcharges. Management expects margins to languish in the 18.5%-20% range for the rest of 2026 before recovering structurally in 2027 by eliminating inefficient operators.
Macro Tailwind: NRP Adoption
The transplant industry's shift toward Normothermic Regional Perfusion (NRP) continues to be a structural driver. NRP penetration reached ~59% of DCD (donation after circulatory death) donors in Q2, up from 57% in Q1. Because NRP yields ~50% more usable organs per DCD donor, Strata's integrated offering is perfectly positioned to capture this volume.
Customer Churn in Logistics
Despite heavily touting a 100% retention rate in recent quarters, management disclosed a non-exclusive customer significantly reduced flying for a specific organ type late in Q2. This will result in an approximate 3% sequential headwind to Q3 Logistics revenue. While management downplayed it as a 'unique set of circumstances', it exposes vulnerability in non-dedicated customer accounts.
Innovative Customer Acquisition: Statline Agreement
Rather than acquiring Statline outright, Strata signed a rolling agreement to assume its Transplant Center Organ Placement relationships. Strata will pay a fee-per-contract (up to $1M aggregate) as customers transition over the next 12 months. This captures up to 8 new clinical customers with zero upfront integration risk, serving as highly efficient lead generation for the broader logistics and clinical funnel.
GAAP vs. Non-GAAP Disconnect
A massive gap exists between GAAP results and the headline Adjusted EBITDA. Net loss from continuing operations widened to $(10.5) million, driven by $5.0 million in accelerated trademark amortization (Blade to Strata rebranding) and $5.5 million in non-cash revaluations of transaction earn-out liabilities. While these are technically non-cash, the constant barrage of 'add-backs' obscures true baseline profitability.
Other KPIs
Strata posted its second consecutive quarter of positive operating cash flow, up from $3.9 million in Q1. This was achieved despite a $1.7 million working capital build required to fund accelerated clinical growth.
Adjusted SG&A remained stable sequentially (down $0.1 million vs Q1), pushing Adjusted SG&A as a percentage of revenue down drastically to 12.6% from 16.4% a year ago, highlighting significant operating leverage post-divestiture.
Guidance
Accelerating. Raised from the prior $260 - $275 million range. The $30 million midpoint boost is driven by $11.5M - $12M from the three Q2 acquisitions, plus outperformance in the base business. H1 revenue was $139.9 million, implying a strong H2 ramp.
Accelerating. Raised from the prior $29 - $33 million range. Acquisitions contribute roughly 3.5% of the raise, with the remainder coming from Clinical segment operating leverage, though partially dragged by the Logistics margin compression.
Stable. Unchanged from prior guidance. The expected bump in EBITDA is entirely offset by anticipated working capital build to support Transplant Clinical growth and nonrecurring transaction-related cash costs.
Decelerating. Plagued by summer seasonality (industry historically dips 3-6%) and a targeted 3% revenue headwind from a non-exclusive customer reducing volume. Expected to recover near Q2 levels by Q4.
Accelerating. Driven by the full-quarter impact of the three newly closed acquisitions and sustained baseline growth in surgical recovery.
Key Questions
Logistics Margin Recovery Path
You expect Logistics margins to return to 20% by 2027 through the elimination of less efficient third-party operators. How much of the current margin gap is structural (fuel surcharge mechanics) versus controllable inefficiencies, and what are the cost implications of shifting capacity to new operators?
Customer Churn Risk
You noted a 3% Logistics revenue headwind from a non-exclusive customer reducing volume. What specific capabilities did the competitor offer to win this volume, and how much of your remaining logistics revenue sits on similar non-exclusive, at-risk contracts?
M&A Integration Bandwidth
With three acquisitions closing in Q2 and a stated expectation that M&A pace will slow in H2, is this deceleration driven by capital preservation, target valuation mismatches, or internal bandwidth constraints as you integrate the new platforms?